METTL3/IGF2BP3 mediates ORC6 via N6-methyladenosine modification to promote the progression of pancreatic ductal adenocarcinoma
Our findings validate the role of ORC6 in PDAC and support the hypothesis that the METTL3/IGF2BP3/ORC6/p53 axis may be a novel therapeutic target for PDAC, and inhibiting this axis may be an advantageous therapeutic strategy for curing PDAC.
Authors
- Kunlei Wang (ORCID: https://orcid.org/0000-0001-6459-2699)
- Zhi‐Nan Chen (ORCID: https://orcid.org/0000-0001-5512-4623)
- Qifeng Wei (ORCID: https://orcid.org/0000-0002-1722-6423)
- Shengyu Wu (ORCID: https://orcid.org/0000-0001-8411-8302)
- Xinyin Li
- Dilinigeer Tayier
- Bo Liao (ORCID: https://orcid.org/0000-0001-9770-5565)
- Qian Cheng (ORCID: https://orcid.org/0000-0003-4362-5783)
- Junwei Liu (ORCID: https://orcid.org/0000-0002-1320-4024)
- Yang Shi
- Zhiyong Yang (ORCID: https://orcid.org/0000-0001-6402-4034)
- Wenjing Song (ORCID: https://orcid.org/0000-0003-2583-4362)
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
Publication Details
- Journal
- Gene
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1016/j.gene.2025.149468
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Wuhan University
- Zhongnan Hospital of Wuhan University